Skip to main content
Qualigen Therapeutics, Inc. logo

Qualigen Therapeutics, Inc. — Investor Relations & Filings

Ticker · QLGN ISIN · US74754R1032 US Professional, scientific and technical activities
Open in API
Filings indexed 618 across all filing types
Latest filing 2020-03-03 Capital/Financing Update
Country US United States of America
Listing US QLGN

About Qualigen Therapeutics, Inc.

https://qlgntx.com/

Qualigen Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for cancer. The company's efforts are directed toward creating therapeutics for both adult and pediatric patients, with a particular emphasis on rare cancers and areas of high unmet medical need. Its development approach combines internal capabilities with collaborations from major cancer research institutions. The company's investigational oncology pipeline includes programs such as QN-302, a Pan-RAS inhibitor platform, and QN-247.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Ritter Pharmaceuticals, Inc. It reports a supplement to a prospectus supplement related to an offering of common stock under a Sales Agreement, increasing the aggregate offering price. It also references a registration statement on Form S-4 related to a merger and proxy solicitation materials to be filed. The document includes legal opinion exhibits and statements about solicitation and offers. The content focuses on capital raising activities and related disclosures, not on full financial results, management discussion, or annual/quarterly reports. The document is not a full financial report but an update on financing and offering activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about financing activities, not just an announcement or certification, so it is not RPA or RNS. Confidence is high due to clear identification as a Form 8-K with financing-related content.
2020-03-03 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5, which is a prospectus supplement filed pursuant to Rule 424(b)(5). It supplements and modifies a previously filed prospectus related to the offer and sale of common stock. The text discusses the terms of the sales agreement, aggregate market value of outstanding shares, and the amount of shares available for sale under the prospectus. This type of filing is related to capital raising activities and updates on financing terms rather than a full financial report or earnings release. It is not an annual or interim report, nor a regulatory certification or voting result. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about the offering, not just an announcement of a report, so it is not an RPA or RNS filing.
2020-03-03 English
425 Filing
Regulatory Filings
2020-03-03 English
Regulatory Filings 2020
Regulatory Filings
2020-02-28 English
FORM 4 SUBMISSION
Director's Dealing
2020-02-28 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a merger, specifically the exchange of warrants for common stock as part of a merger agreement. It includes detailed disclosures about the merger, forward-looking statements, and references to other filings such as Form S-4 and proxy statements. There are no financial statements or comprehensive financial data typical of annual or quarterly reports. The document is not a proxy solicitation itself but references proxy materials to be filed later. It is not an earnings release, audit report, or other specific report type. The primary purpose is to announce a material definitive agreement and related merger activity. Therefore, the most appropriate classification is "Capital/Financing Update (CAP)" because it involves financing activities and merger-related capital transactions disclosed in a Form 8-K.
2020-02-21 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.